These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Interests in angiogenesis inhibitor drugs approved for the treatment of cancers]. Bennis Y; Guillet B; Curti C; Pisano P Therapie; 2010; 65(2):95-105. PubMed ID: 20478241 [TBL] [Abstract][Full Text] [Related]
3. Angiogenesis regulated by VEGF and its receptors and its clinical application. Shibuya M Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401 [No Abstract] [Full Text] [Related]
4. The role of antiangiogenesis therapy: bevacizumab and beyond. Cortés-Funes H Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449 [TBL] [Abstract][Full Text] [Related]
5. [Antiangionic drugs in soft tissue sarcoma]. Salas S; Huynh T; Deville JL; Duffaud F Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703 [TBL] [Abstract][Full Text] [Related]
9. A new weapon for attacking tumor blood vessels. Semenza GL N Engl J Med; 2008 May; 358(19):2066-7. PubMed ID: 18463385 [No Abstract] [Full Text] [Related]
10. Angiogenesis as targeted breast cancer therapy. Hayes DF; Miller K; Sledge G Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641 [TBL] [Abstract][Full Text] [Related]
11. Advances in the use of angiogenesis inhibitors in cancer. Pinedo HM Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080 [No Abstract] [Full Text] [Related]
12. Molecularly targeted therapy in renal cell carcinoma: where do we go from here? Rini BI Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489 [TBL] [Abstract][Full Text] [Related]
13. [Treatment with antiangiogenic drugs]. Saijo N Nihon Rinsho; 2010 Jun; 68(6):1007-13. PubMed ID: 20535948 [TBL] [Abstract][Full Text] [Related]
14. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Quesada AR; Medina MA; Alba E Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210 [TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic and anti-HER therapy. Gasparini G; Sarmiento R; Longo R Biomed Pharmacother; 2006 Jul; 60(6):263-5. PubMed ID: 16815667 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197 [TBL] [Abstract][Full Text] [Related]
18. [Role of angiogenesis inhibitors in the treatment of colorectal cancer]. Bodoky G Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870 [TBL] [Abstract][Full Text] [Related]
19. [Advances of VEGF related molecular promoting tumor angiogenesis and targeting therapy]. Guo ZY; Cao BL Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):282-4. PubMed ID: 20654135 [No Abstract] [Full Text] [Related]
20. [Effect of angiogenesis inhibitors on renal cell carcinoma]. Bodrogi I Magy Onkol; 2007; 51(2):145-53. PubMed ID: 17660871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]